Wall Street brokerages expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report earnings per share (EPS) of ($0.42) for the current quarter, according to Zacks. Zero analysts have made estimates for Aldeyra Therapeutics’ earnings, with estimates ranging from ($0.50) to ($0.36). Aldeyra Therapeutics reported earnings of ($0.38) per share during the same quarter last year, which would suggest a negative year over year growth rate of 10.5%. The firm is scheduled to announce its next earnings results on Monday, November 13th.

On average, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.67) per share for the current fiscal year, with EPS estimates ranging from ($2.12) to ($1.43). For the next financial year, analysts expect that the firm will report earnings of ($1.75) per share, with EPS estimates ranging from ($2.49) to ($1.24). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Aldeyra Therapeutics.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02.

ALDX has been the subject of several recent analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $16.00 target price on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. Canaccord Genuity set a $12.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Zacks Investment Research cut shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. Finally, HC Wainwright set a $18.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $14.15.

In other news, major shareholder Life Sciences Maste Perceptive bought 296,007 shares of Aldeyra Therapeutics stock in a transaction dated Friday, June 30th. The stock was bought at an average price of $4.60 per share, for a total transaction of $1,361,632.20. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 28.40% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Virtu KCG Holdings LLC bought a new stake in shares of Aldeyra Therapeutics during the second quarter valued at approximately $104,000. Vanguard Group Inc. boosted its stake in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after buying an additional 9,407 shares during the period. Sphera Funds Management LTD. boosted its stake in shares of Aldeyra Therapeutics by 31.0% in the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after buying an additional 207,431 shares during the period. Hikari Power Ltd boosted its stake in shares of Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after buying an additional 70,196 shares during the period. Finally, Perceptive Advisors LLC boosted its stake in shares of Aldeyra Therapeutics by 48.7% in the first quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock valued at $12,897,000 after buying an additional 945,000 shares during the period. Hedge funds and other institutional investors own 49.09% of the company’s stock.

Shares of Aldeyra Therapeutics (NASDAQ ALDX) traded up 1.7446% on Tuesday, hitting $4.2224. 17,258 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $4.50 and its 200 day moving average price is $4.69. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $8.19. The stock’s market cap is $26.37 million.

WARNING: “Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) to Post -$0.42 EPS” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/brokerages-anticipate-aldeyra-therapeutics-inc-aldx-to-post-0-42-eps/1536619.html.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.